๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

On Semi-Parametric Models in Occult Tumour Experiments

โœ Scribed by Dr. Shesh N. Rai

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
500 KB
Volume
39
Category
Article
ISSN
0323-3847

No coin nor oath required. For personal study only.

โœฆ Synopsis

Nonparametric statistical analyses of rodent carcinogenicity experiments involving occult tumours of intermediate lethality require numerous interim sacrifices. In recent papers, various semi-parametric analyses have been proposed which specify a parametric relationship between.the death rate in tumourbearing and tumour-free animals as a means of relaxing the requirement for multiple interim sacrifices. These semi-parametric methods involve different combinations of discrete and continuous time scales for the death and tumour-onset processes. The effect of combining different scales on this parametric relationship is studied further and illustrated via an example.

๐Ÿ“œ SIMILAR VOLUMES

A method for comparing semi-parametric m
A method for comparing semi-parametric models with parametric models in competing risks analysis
โœ Jim Wan ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 555 KB

In survival analysis, Cox's regression model is often used to assess the effect of covariates on the time of failure. This semi-parametric model has been extended to the situation where more than one cause of failure is of interest. In this paper, two semi-parametric models for the analysis of compe

Semi-parametric models for mismeasured e
Semi-parametric models for mismeasured exposure information in vaccine trials
โœ Gregory T. Golm; M. Elizabeth Halloran; Ira M. Longini Jr. ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 168 KB

Exposure to infection information is important for estimating vaccine efficacy, but it is difficult to collect and inherently prone to missingness and mismeasurement. It is, therefore, generally not feasible to collect good exposure information on all participants in a large vaccine trial. We discus